Amyloid-β positive individuals with subjective cognitive decline present increased CSF neurofilament light levels that relate to lower hippocampal volume by Sánchez Benavides, Gonzalo et al.
Neurobiology of Aging 104 (2021) 24–31 
Contents lists available at ScienceDirect 
Neurobiology of Aging 
journal homepage: www.elsevier.com/locate/neuaging.org 
Amyloid- β positive individuals with subjective cognitive decline 
present increased CSF neurofilament light levels that relate to lower 
hippocampal volume 
Gonzalo Sánchez-Benavides a , b , c , ∗, Marc Suárez-Calvet a , b , c , d , Marta Milà-Alomà a , b , c , e , 
Eider M. Arenaza-Urquijo a , b , c , Oriol Grau-Rivera a , b , c , d , Grégory Operto a , b , 
Juan Domingo Gispert a , b , f , Natalia Vilor-Tejedor a , e , g , h , Aleix Sala-Vila a , b , Marta Crous-Bou a , i , j , 
José Maria González-de-Echávarri a , b , Carolina Minguillon a , b , c , Karine Fauria a , c , 
Maryline Simon k , Gwendlyn Kollmorgen l , Henrik Zetterberg m , n , o , p , Kaj Blennow m , n , 
José Luis Molinuevo a , q , ∗, For the ALFA Study §
a Barcelona βeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain 
b IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain 
c Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain 
d Servei de Neurologia, Hospital del Mar, Barcelona, Spain 
e Universitat Pompeu Fabra, Barcelona, Spain 
f Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, Madrid, Spain 
g Centre for Genomic Regulation (CRG), The Barcelona Institute for Science and Technology, Barcelona, Spain 
h Erasmus MC. University Medical Center Rotterdam, Department of Clinical Genetics. Rotterdam, The Netherlands 
i Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA 
j Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute 
(IDIBELL). L’Hospitalet de Llobregat, Barcelona, Spain 
k Roche Diagnostics International Ltd, Rotkreuz, Switzerland 
l Roche Diagnostics GmbH, Penzberg, Germany 
m Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden 
n Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 
o Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK 
p UK Dementia Research Institute at UCL, London, UK 
q Present address: H. Lundbeck A/S, Denmark 
a r t i c l e i n f o 
Article history: 
Received 27 October 2020 
Revised 19 February 2021 
Accepted 26 February 2021 
Available online 6 March 2021 
Keywords: 






a b s t r a c t 
Neurofilament light chain (NfL) is an axonal protein that when measured in cerebrospinal fluid (CSF) 
serves as a biomarker of neurodegeneration. We aimed at investigating the association among CSF NfL, 
presence of Subjective Cognitive Decline (SCD) and hippocampal volume, and how CSF amyloid- β (A β) 
modifies these associations. We included 278 cognitively unimpaired participants from the Alfa + cohort 
(78 SCD and 200 Controls). Linear models accounting for covariates (age, gender, and mood) were used to 
test the association between CSF NfL and SCD status, and between CSF NfL and bilateral hippocampal vol- 
umes. Interactions with A β were also explored. Individuals with SCD had higher CSF NfL and lower CSF 
A β42/40 than Controls. There was a significant interaction between SCD and CSF-A β42/40 levels. Strat- 
ified analyses showed a significant association between SCD and NfL only in A β+ individuals. Higher 
CSF NfL was significantly associated with lower hippocampal volume specifically in A β+ individuals with 
SCD. The presence of SCD in A β+ individuals may represent an early symptom in the Alzheimer’s con- 
tinuum related to incipient neurodegeneration. 
© 2021 The Authors. Published by Elsevier Inc. 
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Altered amyloid- β (A β) and phosphorylated tau (p-tau) in
cerebrospinal fluid (CSF) are hallmark biomarker features of
Alzheimer’s disease (AD). Besides these core AD biomarkers,
measures of neuronal injury and neurodegeneration are useful
to stage the severity of the disease ( Jack et al., 2018 ). Neurode-
generation in AD is usually ascertained through brain atrophy in
MRI, FDG-PET hypometabolism or increment of t-tau. CSF and
blood neurofilament Light protein (NfL) measures are also reliable
indicators of neuronal injury ( Gaetani et al., 2019 ; Weston et al.,
2017 ). Neurofilament proteins confer stability to neurons and are
a major determinant of axonal caliber ( Hoffman et al., 1987 ). In
presence of neuronal and axonal damage, NfL is released and it
dramatically increases in CSF or plasma. In the Alzheimer’s contin-
uum , increased NfL levels are associated with low A β42 and high
t-tau and p-tau levels in CSF ( Gangishetti et al., 2018 ; Milà-Alomà
et al., 2020 ; Zetterberg et al., 2016 ), brain atrophy ( Pereira et al.,
2017 ; Zetterberg et al., 2016 ), disease progression ( Mattsson et al.,
2019 , 2017 ; Zetterberg et al., 2016 ), and the severity of cognitive
impairment in Mild Cognitive Impairment (MCI) and AD dementia
patients ( Gangishetti et al., 2018 ; Zetterberg et al., 2016 ). NfL lev-
els also have prognostic value predicting future cognitive decline.
Increased baseline levels of CSF NfL predicted cognitive worsening
in MCI and AD dementia patients ( Mattsson et al., 2016 ). A recent
study found that cognitively unimpaired individuals in the top-
quartile of CSF NfL levels display a threefold risk of developing
MCI after a median 4-year follow up ( Kern et al., 2019 ). 
Subjective cognitive decline (SCD) is defined as the percep-
tion of cognitive difficulties in the absence of objective cognitive
impairment after formal neuropsychological testing ( Jessen et al.,
2014 ). SCD may represent the first clinical symptom of AD, and
several studies demonstrated that increases the risk of having pos-
itive AD core biomarkers ( Jessen et al., 2018 ; Snitz et al., 2015 ;
Wolfsgruber et al., 2017 ). Although SCD individuals have been ex-
tensively characterized in terms of brain features and core AD
biomarkers, the evidence on the association between SCD and
NfL is limited. A recent paper with longitudinal data from the
BIOMARKAPD study included a group of SCD subjects and reported
no differences in CSF NfL levels as compared to controls ( Lleó et al.,
2019 ). Another study performed in cognitively unimpaired elders
(mean age 78 years), reported a trend of elevated plasma NfL con-
centrations in individuals harboring neocortical A β load only when
they have significant memory complaints ( Chatterjee et al., 2018 ).
Similarly, in a recent longitudinal study in the INSIGHT-preAD co-
hort, which is entirely composed by memory complainers (mean
age 76 years), the authors found increments of plasma NfL levels
over 3 years and that baseline NfL was weakly but significantly
associated to increased cortical amyloid deposition at follow-up
( Baldacci et al., 2020 ). In this study, we aimed to further investi-
gate whether there is an association between CSF NfL levels and
the presence of SCD in cognitively unimpaired individuals and to
further assess its relationship with hippocampal volume. In addi-




We included the first 278 consecutively recruited participants
from the ongoing ALFA + study (for ALzheimer and FAmilies).
ALFA + is a research cohort of middle-aged cognitively unimpaired
subjects, many of which are offspring of AD patients (174 out of
278, 62.6%, having at least one parent diagnosed of AD beforeage 75), which have been deeply characterized by clinical inter-
views, lifestyle and risk factors questionnaires, cognitive testing,
CSF biomarkers, and neuroimaging procedures, including magnetic
resonance imaging (MRI), and A β and FDG positron emission to-
mography (PET). All these procedures will be repeated every 3
years with the main aim of identifying the earliest pathophysio-
logical changes in the preclinical AD continuum ( Molinuevo et al.,
2016 ). In the present study, data from the first ALFA + visit,
performed between 2016 and 2019 (concurrent visit) were ana-
lyzed. ALFA + inclusion criteria were: (i) subjects that had previ-
ously participated in the 45-65/FPM2012 study (ALFA parent co-
hort ( Molinuevo et al., 2016 ); (ii) age between 45-75 years at the
moment of the inclusion in the 45-65/FPM2012 study; (iii) long-
term commitment to the study: inclusion and follow-up visits and
agreement to undergo at all tests and study procedures (MRI, PET
and lumbar puncture). ALFA + exclusion criteria included: (i) cog-
nitive impairment (Clinical Dementia Rating [CDR] > 0, Mini Mental
State Examination [MMSE] < 27, semantic fluency < 12); (ii) any sig-
nificant systemic illness or unstable medical condition which could
lead to difficulty complying with the protocol; (iii) any contraindi-
cation to any test or procedure; (iv) family history of monogenic
AD. 
2.2. SCD definition 
Participants completed the Subjective Cognitive Decline-
Questionnaire (SCD-Q) ( Rami et al., 2014 ) at the beginning of the
clinical interview, prior to neuropsychological testing. Presence
or absence of SCD was defined as the positive (SCD) or negative
(Control) answer to the first question of the: Do you perceive
memory or cognitive difficulties? 
2.3. CSF measures 
CSF collection, processing and storage in the ALFA + study have
been described previously ( Milà-Alomà et al., 2020 ). CSF NfL, A β42
and A β40 were measured with the NeuroToolKit robust prototype
assays (Roche Diagnostics, Rotkreuz, Switzerland) on a cobas e 411
or e 601 instrument (Roche Diagnostics, Rotkreuz, Switzerland).
The Roche NeuroToolKit is a panel of exploratory prototype as-
says designed to robustly evaluate biomarkers associated with key
pathologic events characteristic of AD and other neurological dis-
orders. Measurements were performed at the Clinical Neurochem-
istry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
A β status (A β+ , A β-) was defined using the ratio A β42/40 cut-off
of 0.071 ( Milà-Alomà et al., 2020 ). 
2.4. Hippocampal volumes 
We used FreeSurfer version 6.0 automated segmentations of the
hippocampus using T1 scans acquired in a GE 3T scanner (3D-T1;
voxel size = 1mm 3 isotropic). A bilateral hippocampal volume vari-
able was constructed by summing up left and right hemisphere
measurements. The residuals from a linear regression using Total
Intracranial Volume (TIV) as independent variable were used in
the analysis as TIV-adjusted hippocampal volumes. Adjusted hip-
pocampal volumes reflect the deviation in participant’s hippocam-
pal volume from what is expected given their TIV. 
2.5. Additional measurements 
We collected measures of anxiety and depression and car-
diovascular risk factors. Current mood state was recorded with
the Hospital Anxiety and Depression Scale (HADS) ( Zigmond and
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Table 1 
Descriptive data of sociodemographic, APOE - ε4 status, mood and vascular risk score 
by SCD status. 
Controls, n = 200 SCD, n = 78 
Age, mean (SD) 60.56 (4.96) 61.80 (4.32) 
Years of education, mean (SD) 13.42 (3.57) 13.26 (3.56) 
Females, n (%) 129 (64.5%) 53 (67.9%) 
APOE - ε4 carriers, n (%) 88 (44%) 41 (52.6%) 
A β+ , n (%) 58 (29%) 30 (38.5%) 
HADS, mean (SD) 6.3 (4.7) 9.0 (5.2) a 
CAIDE score, mean (SD) 9.2 (2.1) 9.4 (1.8) 
A β positivity defined as A β42/40 ratio below the 0.071 cut-off. 
Key: CAIDE, Cardiovascular Risk Factors, Aging, and Incidence of Dementia risk 
score; HADS, Hospital Anxiety and Depression Scale. 
















































































Snalth, 1983 ). For vascular risk factors we used the CAIDE (Cardio-
vascular Risk Factors, Aging, and Incidence of Dementia) dementia
risk score model 1. In brief, the CAIDE includes categorized vari-
ables (age, education, sex, systolic blood pressure, body mass in-
dex, total cholesterol and physical activity) to calculate a global
score that ranges from 0 to 15 ( Kivipelto et al., 2006 ). 
2.6. Statistical analyses 
We compared mean CSF NfL levels between Controls and SCD
by means of ANCOVA, with CSF NfL as dependent variable, SCD
group as factor, and age, gender and HADS as covariates. Addi-
tional ANCOVA models including continuous and dichotomous CSF
A β42/40 measures and the interaction term SCD ∗A β42/40 were
computed to explore the effect of A β42/40. Further models strat-
ifying by A β status (A β+ and A β- individuals) were also per-
formed. 
The association between CSF NfL and hippocampal volume was
assessed using linear models, with the TIV-adjusted bilateral hip-
pocampal volume as dependent variable, CSF NfL as independent
variable and age and gender as covariates. Separate models includ-
ing interaction terms SCD ∗CSF NfL and CSF A β42/40 ∗SCD were ran
and further stratified analyses by A β-status and SCD groups were
performed. 
Additional analysis further including the CAIDE risk score as a
covariate were conducted to elucidate if vascular risk had an effect
in the observed associations. The logarithmic transformation of CSF
NfL, log 10 (NfL), was used in all analyses to meet the assumption of
normality. Significance was assumed at the level of p < 0.05 for
main effects and at p < 0.1 for interactions. 
3. Results 
Seventy-eight out of the 278 individuals (28.1%) were classified
as having SCD. There were no differences between Controls and
SCD in age, education, CAIDE score, gender or APOE - ε4 status. SCD
subjects had higher scores in the HADS, reflecting a higher degree
of anxiety and depressive symptoms ( Table 1 ). 
3.1. Differences in CSF NfL, CSF A β42/40 and neuroimaging measures 
between SCD and controls 
Descriptive data for CSF and neuroimaging measures are shown
in Table 2 . SCD individuals had higher CSF NfL ( p = 0.002, Partial
η2 = 0.033) and lower CSF A β42/40 ( p = 0.044, Partial η2 = 0.015)
with respect to Controls after adjusting by age, gender and HADS
score. 
When the CSF A β42/40 was introduced as a covariate in the
model (without modeling interactions) the differences in CSF NfLbetween SCD and Controls remained significant ( p = 0.008, Par-
tial η2 = 0.026). In models including interaction terms we found
significant interactions between SCD and both continuous and di-
chotomous A β measures (SCD ∗CSF A β42/40, p = 0.028, Partial
η2 = 0.018; SCD ∗A β-status, p = 0.065, Partial η2 = 0.013; see
Table 3 and Fig. 1 ). 
With regard to neuroimaging measures, no differences in hip-
pocampal and TIV volumes were found between SCD and Controls.
3.2. SCD effect on CSF NfL stratified by A β status 
We observed significant differences in CSF NfL between SCD
and Controls in A β+ individuals (n = 88, p = 0.01, Partial
η2 = 0.079), while no significant differences were found in the A β-
group (n = 190) ( p = 0.13, Partial η2 = 0.012). 
3.3. Association between CSF NfL and hippocampal volume 
Hippocampal volume was not associated to CSF NfL in the
whole sample ( p = 0.49). We found a significant interaction with
A β status (A β∗NfL, p = 0.09), but not with SCD status (SCD ∗CSF
NfL, p = 0.48). In stratified analyses by A β status a trend for
a negative association was observed in the A β+ group (Beta =
−1.19, p = 0.13), but not in A β- individuals ( p = 0.44). We fur-
ther stratified these groups by SCD status and observed a signifi-
cant association only in those A β+ that also display SCD (n = 30),
in which a moderate negative relationship was observed (Beta =
−3.0, p = 0.039, age-adjusted r = 0.38; see Table 4 and Fig. 2 ). 
3.4. Models adjusted by cardiovascular risk score 
We repeated the analyses including the CAIDE as an additional
covariate to rule out the effect of cardiovascular damage and no
changes in interactions and stratified results were observed. Differ-
ences in CSF NfL between SCD and Controls after stratifying by A β
status remained significant only in A β+ individuals ( p = 0.014) as
well as the association between hippocampal volume and CSF NfL
in SCD individuals that are A β+ (Beta = −3.2, p = 0.029). 
4. Discussion 
In this study, we aimed to investigate the effect of SCD in CSF
NfL levels, the association between NfL and hippocampal volumes
and the interaction with A β . Our results show that CSF NfL is el-
evated in cognitively unimpaired SCD individuals as compared to
Controls, and this difference is driven by A β+ individuals. Addi-
tionally, there is a negative association between CSF NfL levels and
hippocampal volumes only in A β+ individuals that also have SCD.
These associations are independent of age, gender, mood and car-
diovascular risk. 
Our results showing increased CSF NfL in SCD individuals are in
line with previous studies that have found evidences of neurode-
generation in this population using other biomarkers such as re-
duced medial temporal lobe volume ( Hu et al., 2019 ; Jessen et al.,
2006 ; Perrotin et al., 2015 ; Scheef et al., 2012 ) and FDG-PET
hypometabolism in AD-vulnerable regions ( Scheef et al., 2012 ;
Van Der Gucht et al., 2015 ). Studies using CSF t-tau found a rela-
tively small percentage of SCD individuals above the cut-offs of ab-
normality, between 18 and 31% ( Hu et al., 2019 ; Wolfsgruber et al.,
2019 , 2017), and mean levels consistently did not show differences
as compared to controls ( Lleó et al., 2019 ; Miebach et al., 2019 ;
Valech et al., 2018 ; Wolfsgruber et al., 2020 , 2017). Therefore, CSF
NfL may be a more sensitive biomarker of neurodegeneration than
t-tau in SCD. Although the only study directly comparing CSF NfL
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Table 2 
Descriptive data of CSF and neuroimaging measures by SCD status. 
Controls, n = 200 SCD, n = 78 
CSF NfL (pg/ml), mean (SD) 77.85 (27.17) 91.38 (35.78) b 
CSF A β42/40, mean (SD) 0.08 (0.02) 0.07 (0.02) a 
Right hippocampal volume (mm 3 ), mean (SD) 3255 (305) 3221 (307) 
Left hippocampal volume (mm 3 ), mean (SD) 3226 (318) 3190 (325) 
Total intracranial volume (TIV, cm 3 ), mean (SD) 1439.7 (173.3) 1430.7 (163.6) 
a p < 0.05. 
b p < 0.01, adjusted by age, gender, and HADS. 
Table 3 
Results from the linear models with NfL as the dependent variable, without (Model 1) and with 
cardiovascular risk adjustment (Model 2). 
Model 1 Model 2 
β value 95% CI p value β value 95% p value 
SCD 0.086 0.032-0.140 0.002 0.083 0.029-0.138 0.003 
A β 0.112 0.057-0.168 < 0.001 0.111 0.055-0.166 < 0.001 
Age 0.013 0.010-0.016 < 0.001 0.014 0.011-0.017 < 0.001 
Gender 0.071 0.040-0.102 < 0.001 0.073 0.041-0.103 < 0.001 
HADS score 0.000 −0.003-0.003 0.827 0.000 −0.003-0.003 0.948 
CAIDE score - - - −0.008 −0.019-0.003 0.131 
SCD ∗A β 0.063 −0.004-0.129 0.065 0.062 −0.005-0.130 0.071 
A β positivity defined as A β42/40 ratio below the 0.071 cut-off. 
Key: CAIDE, Cardiovascular Risk Factors, Aging, and Incidence of Dementia risk score; HADS, Hos- 
pital Anxiety and Depression Scale; SCD, Subjective Cognitive Decline. 
Table 4 
Results from the linear models with TIV-adjusted hippocampal volume as the dependent vari- 
able in the stratified sample. Models without (Model 1) and with cardiovascular risk adjustment 
(Model 2) in extreme subgroups (A β− Controls and A β+ with SCD) are shown. 
Model 1 Model 2 
β value 95% CI p value β value 95% p value 
A β− Controls (n = 142) 
Age −0.050 −0.092 −0.009 0.017 −0.042 −0.086-0.003 0.069 
Gender 0.198 −0.185-0.581 0.309 0.273 −0.120-0.667 0.172 
NfL 0.425 −1.038-1.887 0.567 0.338 −1.169-1.845 0.658 
CAIDE score - - - −0.053 −0.184-0.078 0.425 
A β+ with SCD (n = 30) 
Age 0.000 −0.097-0.096 0.995 −0.003 −0.098-0.092 0.950 
Gender 0.311 −0.552-1.173 0.466 0.037 −0.905-0.979 0.936 
NfL −3.050 −5.932 −0.167 0.039 −3.211 −6.060 −0.32 0.029 
CAIDE score - - - 0.215 −0.105-0.534 0.179 
Key: CAIDE, Cardiovascular Risk Factors, Aging, and Incidence of Dementia risk score; HADS, Hos- 
pital Anxiety and Depression Scale. 
Fig. 1. Interaction effect between A β and SCD status on CSF NfL levels. Age and mood-adjusted log values for NfL are plotted. SCD, Subjective cognitive decline; A β , amyloid- 
beta status defined by CSF A β42/40. 
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Fig. 2. Association between hippocampal volume and CSF NfL by A β status and SCD groups. Log values for NfL are plotted. SCD, Subjective cognitive decline; A β , amyloid- 







































































levels between SCD and control individuals reported no signifi-
cant differences ( Lleó et al., 2019 ), such divergent findings may
be explained by differences in recruitment methods and sample
characteristics. Although sample sizes of SCD groups in both stud-
ies are similar (75 vs 78), our study was mono-centric, while in
the BIOMARKAPD study the sample was recruited from 13 dif-
ferent sites, including both clinical and non-clinical cohorts. It is
known that recruitment setting influences results in SCD popula-
tions ( Rodríguez-Gómez et al., 2015 ), therefore, heterogeneity in
SCD definitions by center may had have an impact on their results.
Also, our sample was enriched in AD risk factors as compared to
theirs (e.g. APOE - ε4 frequency in SCD 52.6%vs 19.4%) and we ob-
served a significant increase of A β pathology in our SCD group.
Considering that differences in CSF NfL in our study were driven
by SCD individuals with higher A β pathology, the lower A β burden
in the previous study may also underlie the contrasting findings. 
Although CSF NfL is generally associated to A β pathology, it
has been suggested that CSF NfL reflects A β-independent neu-
rodegeneration and clinical progression in AD ( Kern et al., 2019 ;
Mattsson et al., 2016 ; Zetterberg et al., 2016 ). However, our results
provide evidence of an interplay between SCD and NfL levels
that is clearly influenced by A β status. This is in line with the
trend reported by Chatterjee et al. in their study ( Chatterjee et al.,
2018 ), in which plasma NfL was slightly increased only in those
individuals in which a positive amyloid status and SCD concur,
and also with the positive association between plasma NfL levels
and baseline and longitudinal brain amyloid deposition observed
by Baldacci et al in memory complainers ( Baldacci et al., 2020 ).
These findings support the notion that SCD may be an early
indicator of neurodegeneration in individuals that are already
in the Alzheimer’s continuum (A β+ ). This is further supported
by the observed associations between CSF NfL and hippocampal
volumes, in which a moderate association was found only in A β+
individuals that also had SCD. Hippocampal atrophy paralleling in-
creasing CSF NfL has been consistently described in cross-sectional
and longitudinal studies in both symptomatic and cognitively
unimpaired subjects ( Mattsson et al., 2019 , 2016; Zetterberg et al.,2016 ) but this is the first study that found an effect of SCD status
in such association in cognitively unimpaired individuals. 
Since CSF NfL levels may be increased in individuals with
vascular-related brain damage ( Mielke et al., 2019 ) we further
adjusted the main analysis by the CAIDE risk score, composed
by well-known cardiovascular risk variables (including cholesterol,
body mass index, blood pressure levels and physical activity). The
inclusion of this variable in the models did not change the ob-
served associations, suggesting that they are independent of vas-
cular risk factors, and replicates the recent results in plasma NfL
observed in the INISGHT-PreAD study, in which vascular risk fac-
tors neither influenced this measure in SCD ( Baldacci et al., 2020 ).
Globally, both findings give further support to the usefulness of NfL
measures as a reliable marker of neurodegeneration in the early
stages of Alzheimer’s disease. 
A recent study on the dynamics of cognition and biomark-
ers across the spectrum of AD suggest that changes in CSF NfL
occur approximately at the same time as memory decline and
A β42 changes in CSF ( Hadjichrysanthou et al., 2020 ). If our find-
ings are confirmed, CSF A β42/40 and NfL may be useful as an
early biomarker of mild neurodegeneration underpinning the ex-
perienced subtle cognitive changes that triggers the subjective per-
ception of decline. 
This study is not free of limitations. The cross-sectional nature
of the measures prevents us from drawing conclusions on the
impact of CSF NfL on the clinical progression of SCD individuals.
However, the follow-up of the ALFA + cohort is undergoing and
future studies will help to elucidate this. Another limitation of
this study relates to the overlook of tau pathology measures in
the analysis. Increased NfL levels are associated to elevated tau
pathology and, therefore, we cannot rule out a possible effect of
tau levels in the observed associations. Future analysis will explore
such relationships. We would like to highlight that although the
size of the global sample can be considered adequate, the smaller
number of individuals per group in the stratified analyses should
be taking into account when interpreting the findings, that need
to be replicated in larger samples. Finally, this sample is composed









































































































of cognitively unimpaired individuals at increased risk of AD that
participate in a research project, and is well known that the
setting of recruitment of SCD (memory clinics vs general popu-
lation) highly impacts the outcomes ( Abdelnour et al., 2017 ) and
therefore the generalizability of the present results. 
In conclusion, our results suggest that SCD may be associated
to neurodegeneration as measured by CSF NfL, and this association
seems related to underling A β pathology. Thus, subjective reports
of cognitive decline in A β+ individuals may indicate the presence
of AD-related neurodegeneration. 
Author contribution 
Gonzalo Sánchez-Benavides: Conceptualization, Formal analysis,
Investigation, Writing - original draft. Marc Suárez-Calvet: Concep-
tualization, Investigation, Methodology, Writing - review & editing.
Marta Milà-Alomà: Investigation. Eider M. Arenaza-Urquijo: Con-
ceptualization, Writing - review & editing. Oriol Grau-Rivera: Con-
ceptualization, Investigation, Writing - review & editing. Grégory
Operto: Data curation, Investigation, Software. Juan Domingo Gis-
pert: Supervision, Writing - review & editing. Natalia Vilor-Tejedor:
Methodology, Writing - review & editing. Aleix Sala-Vila: Concep-
tualization, Writing - review & editing. Marta Crous-Bou: Concep-
tualization, Methodology, Writing - review & editing. José Maria
González-de-Echávarri: Investigation, Visualization. Carolina Min-
guillon: Project administration, Writing - review & editing. Karine
Fauria: Project administration. Maryline Simon: Resources, Writing
- review & editing. Gwendlyn Kollmorgen: Resources, Writing - re-
view & editing. Henrik Zetterberg: Resources, Writing - review &
editing. Kaj Blennow: Resources, Writing - review & editing. José
Luis Molinuevo: Conceptualization, Supervision, Writing - review
& editing 
Conceptualization, Data curation, Formal analysis, Fund-
ing acquisition, Investigation, Methodology, Project administra-
tion, Resources, Software, Supervision, Validation, Visualization,
Roles/Writing - original draft, Writing - review & editing. 
Submission declaration and verification 
The work described in this manuscript has not been published
previously and it is not under consideration for publication else-
where. Its publication is approved by all authors and tacitly or
explicitly by the responsible authorities where the work was car-
ried out, and, if accepted, it will not be published elsewhere in the
same form, in English or in any other language, including electron-
ically without the written consent of the copyright-holder. 
Disclosure statement 
JLM has served/serves as a consultant or at advisory boards
for the following for-profit companies, or has given lectures in
symposia sponsored by the following for-profit companies: Roche
Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly,
Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare,
ProMIS Neurosciences, NovoNordisk, Zambón, Cytox and Nutricia. 
HZ has served at scientific advisory boards for Denali, Roche
Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Ther-
apeutics and CogRx, has given lectures in symposia sponsored
by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain
Biomarker Solutions in Gothenburg AB (BBS), which is a part of
the GU Ventures Incubator Program (outside submitted work). 
KB has served as a consultant, at advisory boards, or
at data monitoring committees for Abcam, Axon, Biogen,
JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Roche
Diagnostics, and Siemens Healthineers, and is a co-founder ofBrain Biomarker Solutions in Gothenburg AB (BBS), which is a
part of the GU Ventures Incubator Program. KB has served as a
consultant, at advisory boards, or at data monitoring committees
for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly,
MagQu, Novartis, Roche Diagnostics, and Siemens Healthineers,
and is a co-founder of Brain Biomarker Solutions in Gothenburg
AB (BBS), which is a part of the GU Ventures Incubator Program. 
MS is a full-time employee and shareholder of Roche Diagnos-
tics International, Ltd. 
GK is a full-time employee of Roche Diagnostics GmbH. 
The rest of the authors have no conflict of interest to declare. 
Acknowledgments 
Collaborators of the ALFA study are: Annabella Beteta, Raf-
faele Cacciaglia, Alba Cañas, Carme Deulofeu, Irene Cumplido, Ruth
Dominguez, Maria Emilio, Carles Falcon, Sherezade Fuentes, Laura
Hernandez, Gema Huesa, Jordi Huguet, Karine Fauria, Paula Marne,
Tania Menchón, Albina Polo, Sandra Pradas, Gemma Salvadó, Anna
Soteras and Marc Vilanova. 
The authors thank Roche Diagnostics International Ltd. for pro-
viding the kits to measure CSF biomarkers, and the laboratory
technicians at the Clinical Neurochemistry Lab in Mölndal, Swe-
den, who performed the analyses. ELECSYS, COBAS and COBAS E
are registered trademarks of Roche. The Elecsys β-Amyloid (1-42)
CSF immunoassay in use is not a commercially available IVD as-
say. It is an assay that is currently under development and for in-
vestigational use only. The measuring range of the assay is 200
(lower technical limit) – 1700 pg/mL (upper technical limit). The
performance of the assay beyond the upper technical limit has not
been formally established. Therefore, use of values above the up-
per technical limit, which are provided based on an extrapolation
of the calibration curve, is restricted to exploratory research pur-
poses and is excluded for clinical decision making. This publication
is part of the ALFA study (ALzheimer and FAmilies). The authors
would like to express their most sincere gratitude to the ALFA
project participants, without whom this research would have not
been possible. The authors thank Roche Diagnostics International
Ltd. for providing the kits to measure CSF biomarkers, and the lab-
oratory technicians at the Clinical Neurochemistry Lab in Mölndal,
Sweden, who performed the analyses. ELECSYS, COBAS and COBAS
E are registered trademarks of Roche. The Elecsys β-Amyloid (1-
42) CSF immunoassay in use is not a commercially available IVD
assay. It is an assay that is currently under development and for
investigational use only. The measuring range of the assay is 200
(lower technical limit) 1700 pg/mL (upper technical limit). The per-
formance of the assay beyond the upper technical limit has not
been formally established. Therefore, use of values above the up-
per technical limit, which are provided based on an extrapolation
of the calibration curve, is restricted to exploratory research pur-
poses and is excluded for clinical decision making. 
The research leading to these results has received funding
from “la Caixa” Foundation (LCF/PR/GN17/1030 0 0 04) and the
Alzheimer’s Association and an international anonymous char-
ity foundation through the TriBEKa Imaging Platform project
(TriBEKa-17-519007). Additional support has been received from
the Universities and Research Secretariat, Ministry of Business
and Knowledge of the Catalan Government under the grant no.
2017-SGR-892. MS-C received funding from the European Union’s
Horizon 2020 Research and Innovation Program under the Marie
Sklodowska-Curie action grant agreement No 752310, and cur-
rently receives funding from the Spanish Ministry of Science,
Innovation and Universities (Juan de la Cierva Programme grant
IJC2018-037478-I ). EMA-U is supported by the Spanish Ministry
of Science, Innovation and Universities - Spanish State Research











































































































































Agency ( RYC2018-026053-I ) and is recipient of the Alzheimer’s
Association Research Grant ( AARC 2019-AARG 6 446 41 ). OG-R is
supported by the Spanish Ministry of Science, Innovation and Uni-
versities ( FJCI-2017-33437 ). JDG holds a ‘Ramón y Cajal’ fellowship
( RYC-2013-13054 ). NV-T is funded by a post-doctoral grant, Juan
de la Cierva Programme ( FJC2018-038085-I ), Ministry of Science
and Innovation– Spanish State Research Agency. ASV is the recip-
ient of an Instituto de Salud Carlos III Miguel Servet II fellowship
( CP II 17/0 0 029 ). HZ is a Wallenberg Scholar supported by grants
from the Swedish Research Council (# 2018-02532 ), the European
Research Council (# 681712 ), Swedish State Support for Clinical
Research (# ALFGBG-720931 ), the Alzheimer Drug Discovery Foun-
dation (ADDF), USA (# 201809-2016862 ), and the UK Dementia
Research Institute at UCL. KB is supported by the Alzheimer Drug
Discovery Foundation (ADDF), USA (# RDAPB-201809-2016615 ),
the Swedish Alzheimer Foundation (# AF-742881 ), Hjärnfonden ,
Sweden (# FO2017-0243 ), the Swedish state under the agreement
between the Swedish government and the County Councils, the
ALF-agreement (# ALFGBG-715986 ), and European Union Joint
Program for Neurodegenerative Disorders ( JPND2019-466-236 ). 
References 
Abdelnour, C., Rodríguez-Gómez, O., Alegret, M., Valero, S., Moreno-Grau, S.,
Sanabria, Á., Hernández, I., Rosende-Roca, M., Vargas, L., Mauleón, A.,
Sánchez, D., Espinosa, A., Ortega, G., Pérez-Cordón, A., Diego, S., Gailhajanet, A.,
Guitart, M., Sotolongo-Grau, Ó., Ruiz, A., Tárraga, L., Boada, M., 2017. Impact of
recruitment methods in subjective cognitive decline. J. Alzheimers Dis. 57, 625–
632. doi: 10.3233/JAD-160915 . 
Baldacci, F., Lista, S., Manca, M.L., Chiesa, P.A., Cavedo, E., Lemercier, P., Zetter-
berg, H., Blennow, K., Habert, M.O., Potier, M.C., Dubois, B., Vergallo, A., Ham-
pel, H., 2020. Age and sex impact plasma NFL and t-Tau trajectories in individ-
uals with subjective memory complaints: a 3-year follow-up study. Alzheimers
Res. Ther. 12, 1–12. doi: 10.1186/s13195- 020- 00704- 4 . 
Chatterjee, P., Goozee, K., Sohrabi, H.R., Shen, K., Shah, T., Asih, P.R., Dave, P.,
Manyan, C., Taddei, K., Chung, R., Zetterberg, H., Blennow, K., Martins, R.N.,
2018. Association of plasma neurofilament light chain with neocortical amyloid-
β load and cognitive performance in cognitively normal elderly participants. J.
Alzheimers Dis. 63, 479–487. doi: 10.3233/JAD-180025 . 
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., Zetterberg, H., 2019.
Neurofilament light chain as a biomarker in neurological disorders. J. Neurol.
Neurosurg. Psychiatry 1–12. doi: 10.1136/jnnp- 2018- 320106 . 
Gangishetti, U., Howell, Christina, J., Perrin, R.J., Louneva, N., Watts, K.D., Kollhoff,
A., Grossman, M., Wolk, D.A., Shaw, L.M., Morris, J.C., Trojanowski, J.Q., Fa-
gan, A.M., Arnold, S.E., Hu, W.T., 2018. Non-beta-amyloid/tau cerebrospinal fluid
markers inform staging and progression in Alzheimer’s disease. Alzheimers Res.
Ther. 10, 98. doi: 10.1186/s13195-018-0426-3 . 
Hadjichrysanthou, C., Evans, S., Bajaj, S., Siakallis, L.C., McRae-McKee, K., de
Wolf, F., Anderson, R.M., 2020. The dynamics of biomarkers across the clini-
cal spectrum of Alzheimer’s disease. Alzheimers. Res. Ther. 12, 74. doi: 10.1186/
s13195- 020- 00636- z . 
Hoffman, P.N., Cleveland, D.W., Griffin, J.W., Landes, P.W., Cowan, N.J., Price, D.L.,
1987. Neurofilament gene expression: a major determinant of axonal caliber.
Proc. Natl. Acad. Sci. U. S. A. 84, 3472–3476. doi: 10.1073/pnas.84.10.3472 . 
Hu, X., Teunissen, C.E., Spottke, A., Heneka, M.T., Düzel, E., Peters, O., Li, S., Priller, J.,
Buerger, K., Teipel, S., Laske, C., Verfaillie, S.C.J., Barkhof, F., Coll-Padrós, N.,
Rami, L., Molinuevo, J.L., van der Flier, W.M., Jessen, F., 2019. Smaller me-
dial temporal lobe volumes in individuals with subjective cognitive decline
and biomarker evidence of Alzheimer’s disease—data from three memory clinic
studies. Alzheimers Dement. 15, 185–193. doi: 10.1016/j.jalz.2018.09.002 . 
Jack, C.R., Bennett, D.A., Blennow, K., Carrillo, M.C., Dunn, B., Haeberlein, S.B., Holtz-
man, D.M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J.L., Montine, T.,
Phelps, C., Rankin, K.P., Rowe, C.C., Scheltens, P., Siemers, E., Snyder, H.M., Sper-
ling, R., Elliott, C., Masliah, E., Ryan, L., Silverberg, N., 2018. NIA-AA research
framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s
Dement. 14, 535–562. doi: 10.1016/j.jalz.2018.02.018 . 
Jessen, F., Amariglio, R.E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chéte-
lat, G., Dubois, B., Dufouil, C., Ellis, K.A., van der Flier, W.M., Glodzik, L.,
van Harten, A.C., de Leon, M.J., McHugh, P., Mielke, M.M., Molinuevo, J.L.,
Mosconi, L., Osorio, R.S., Perrotin, A., Petersen, R.C., Rabin, L.A., Rami, L., Reis-
berg, B., Rentz, D.M., Sachdev, P.S., de la Sayette, V., Saykin, A.J., Scheltens, P.,
Shulman, M.B., Slavin, M.J., Sperling, R.A., Stewart, R., Uspenskaya, O., Vel-
las, B., Visser, P.J., Wagner, M.Subjective Cognitive Decline Initiative (SCD-I)
Working Group, 2014. A conceptual framework for research on subjective cog-
nitive decline in preclinical Alzheimer’s disease. Alzheimer’s Dement. 10, 844–
852. doi: 10.1016/j.jalz.2014.01.001 . 
Jessen, F., Feyen, L., Freymann, K., Tepest, R., Maier, W., Heun, R., Schild, H.H.,
Scheef, L., 2006. Volume reduction of the entorhinal cortex in subjective mem-ory impairment. Neurobiol. Aging 27, 1751–1756. doi: 10.1016/j.neurobiolaging.
2005.10.010 . 
Jessen, F., Spottke, A., Boecker, H., Brosseron, F., Buerger, K., Catak, C., Fliessbach, K.,
Franke, C., Fuentes, M., Heneka, M.T., Janowitz, D., Kilimann, I., Laske, C.,
Menne, F., Nestor, P., Peters, O., Priller, J., Pross, V., Ramirez, A., Schneider, A.,
Speck, O., Spruth, E.J., Teipel, S., Vukovich, R., Westerteicher, C., Wiltfang, J.,
Wolfsgruber, S., Wagner, M., Düzel, E., 2018. Design and first baseline data of
the DZNE multicenter observational study on predementia Alzheimer’s disease
(DELCODE). Alzheimers Res. Ther. 10. doi: 10.1186/s13195- 017- 0314- 2 . 
Kern, S., Syrjanen, J.A., Blennow, K., Zetterberg, H., Skoog, I., Waern, M., Hagen, C.E.,
Van Harten, A.C., Knopman, D.S., Jack, C.R., Petersen, R.C., Mielke, M.M., 2019.
Association of cerebrospinal fluid neurofilament light protein with risk of mild
cognitive impairment among individuals without cognitive impairment. JAMA
Neurol 76, 187–193. doi: 10.1001/jamaneurol.2018.3459 . 
Kivipelto, M., Ngandu, T., Laatikainen, T., Winblad, B., Soininen, H., Tuomilehto, J.,
2006. Risk score for the prediction of dementia risk in 20 years among middle
aged people: a longitudinal, population-based study. Lancet Neurol 5, 735–741.
doi: 10.1016/S1474- 4422(06)70537- 3 . 
Lleó, A., Alcolea, D., Martínez-Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simon-
sen, A.H., Verbeek, M.M., Rosa-Neto, P., Slot, R.E.R., Tainta, M., Izaguirre, A.,
Reijs, B.L.R., Farotti, L., Tsolaki, M., Vandenbergue, R., Freund-Levi, Y., Ver-
hey, F.R.J., Clarimón, J., Fortea, J., Frolich, L., Santana, I., Molinuevo, J.L.,
Lehmann, S., Visser, P.J., Teunissen, C.E., Zetterberg, H., Blennow, K., 2019. Lon-
gitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s dis-
ease continuum in the BIOMARKAPD study. Alzheimers Dement. 15, 742–753.
doi: 10.1016/j.jalz.2019.01.015 . 
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., Weiner, M.W.,
Aisen, P.Toga, A.W., Petersen, R., Jack, C.R., Jagust, W., Trojanowki, J.Q., Shaw,
L.M., Beckett, L., Green, R.C., Saykin, A.J., Morris, J.C., Khachaturian, Z., Sorensen,
G., Carrillo, M., Kuller, L., Raichle, M., Holtzman, D., Paul, S., Davies, P., Fillit,
H., Hefti, F., Mesulam, M.M., Potter, W., Snyder, P., Lilly, E., Schwartz, A., Mon-
tine, T., Thomas, R.G., Donohue, M., Walter, S., Gessert, D., Sather, T., Jiminez,
G., Balasubramanian, A.B., Mason, J., Sim, I., Harvey, D., Bernstein, M., Borowski,
B., Gunter, J., Senjem, M., Vemuri, P., Jones, D., Kantarci, K., Ward, C., Fox, N.,
Thompson, P., Schuff, N., DeCarli, C., Landau, S., Koeppe, R.A., Foster, N., Reiman,
E.M., Chen, K., Mathis, C., Cairns, N.J., Franklin, E., Taylor-Reinwald, L., Lee, V.,
Korecka, M., Figurski, M., Crawford, K., Neu, S., Foroud, T.M., Shen, L., Faber,
K., Kim, S., Nho, K., Potkin, S., Thal, L., Albert, M., Frank, R., Hsiao, J., Kaye, J.,
Quinn, J., Silbert, L., Lind, B., Carter, R., Dolen, S., Schneider, L.S., Pawluczyk,
S., Becerra, M., Teodoro, L., Spann, B.M., Brewer, J., Vanderswag, H., Fleisher, A.,
Heidebrink, J.L., Lord, J.L., Mason, S.S., Albers, C.S., Knopman, D., Johnson, Kris,
Doody, R.S., Villanueva-Meyer, J., Pavlik, V., Shibley, V., Chowdhury, M., Roun-
tree, S., Dang, M., Stern, Y., Honig, L.S., Bell, K.L., Ances, B., Carroll, M., Creech,
M.L., Mintun, M.A., Schneider, S., Oliver, A., Marson, D., Geldmacher, D., Love,
M.N., Griffith, R., Clark, D., Brockington, J., Roberson, E., Grossman, H., Mitsis, E.,
Shah, R.C., De Toledo-Morrell, L., Duara, R., Greig-Custo, M.T., Barker, W., Onyike,
C., D’Agostino, D., Kielb, S., Sadowski, M., Sheikh, M.O., Ulysse, A., Gaikwad, M.,
Doraiswamy, P.M., Petrella, J.R., Borges-Neto, S., Wong, T.Z., Coleman, E., Arnold,
S.E., Karlawish, J.H., Wolk, D.A., Clark, C.M., Smith, C.D., Jicha, G., Hardy, P., Sinha,
P., Oates, E., Conrad, G., Lopez, O.L., Oakley, M.A., Simpson, D.M., Porsteinsson,
A.P., Goldstein, B.S., Martin, K., Makino, K.M., Ismail, M.S., Brand, C., Preda, A.,
Nguyen, D., Womack, K., Mathews, D., Quiceno, M., Levey, A.I., Lah, J.J., Cellar,
J.S., Burns, J.M., Swerdlow, R.H., Brooks, W.M., Apostolova, L., Tingus, K., Woo,
E., Silverman, D.H.S., Lu, P.H., Bartzokis, G., Graff-Radford, N.R., Parfitt, F., Poki-
Walker, K., Farlow, M.R., Hake, A.M., Matthews, B.R., Brosch, J.R., Herring, S.,
Van Dyck, C.H., Carson, R.E., MacAvoy, M.G., Varma, P., Chertkow, H., Bergman,
H., Hosein, C., Black, S., Stefanovic, B., Caldwell, C., Hsiung, G.Y.R., Mudge, B.,
Sossi, V., Feldman, H., Assaly, M., Finger, E., Pasternack, S., Rachisky, I., Trost,
D., Kertesz, A., Bernick, C., Munic, D., Rogalski, E., Lipowski, K., Weintraub, S.,
Bonakdarpour, B., Kerwin, D., Wu, C.K., Johnson, N., Sadowsky, C., Villena, T.,
Turner, R.S., Johnson, Kathleen, Reynolds, B., Sperling, R.A., Marshall, G., Yesav-
age, J., Taylor, J.L., Lane, B., Rosen, A., Tinklenberg, J., Sabbagh, M.N., Belden, C.M.,
Jacobson, S.A., Sirrel, S.A., Kowall, N., Killiany, R., Budson, A.E., Norbash, A., John-
son, P.L., Obisesan, T.O., Wolday, S., Allard, J., Lerner, A., Ogrocki, P., Tatsuoka, C.,
Fatica, P., Fletcher, E., Maillard, P., Olichney, J., Carmichael, O., Kittur, S., Borrie,
M., Lee, T.Y., Bartha, R., Johnson, S., Asthana, S., Carlsson, C.M., Tariot, P., Burke,
A., Milliken, A.M., Trncic, N., Reeder, S., Bates, V., Capote, H., Rainka, M., Scharre,
D.W., Kataki, M., Kelley, B., Zimmerman, E.A., Celmins, D., Brown, A.D., Pearlson,
G.D., Blank, K., Anderson, K., Flashman, L.A., Seltzer, M., Hynes, M.L., Santulli,
R.B., Sink, K.M., Gordineer, L., Williamson, J.D., Garg, P., Watkins, F., Ott, B.R.,
Tremont, G., Daiello, L.A., Salloway, S., Malloy, P., Correia, S., Rosen, H.J., Miller,
B.L., Perry, D., Mintzer, J., Spicer, K., Bachman, D., Pasternak, S., Rachinsky, I.,
Rogers, J., Drost, D., Pomara, N., Hernando, R., Sarrael, A., Schultz, S.K., Smith,
K.E., Koleva, H., Nam, K.W., Shim, H., Relkin, N., Chiang, G., Lin, M., Ravdin, L.,
Smith, A., Raj, B.A., Fargher, K., 2017. Association of plasma neurofilament light
with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74,
557–566. doi: 10.1001/jamaneurol.2016.6117 . 
Mattsson, N., Cullen, N.C., Andreasson, U., Zetterberg, H., Blennow, K., 2019. Asso-
ciation between longitudinal plasma neurofilament light and neurodegenera-
tion in patients with Alzheimer disease. JAMA Neurol 76, 791–799. doi: 10.1001/
jamaneurol.2019.0765 . 
Mattsson, N. , Insel, P.S. , Palmqvist, S. , Portelius, E. , Zetterberg, H. , Weiner, M. ,
Blennow, K. , Hansson, O. , 2016. Cerebrospinal fluid tau, neurogranin, and neu-
rofilament light in Alzheimer’s disease. EMBO Mol Med 8, 1184–1196 . 





































































Miebach, L., Wolfsgruber, S., Polcher, A., Peters, O., Menne, F., Luther, K., Ince-
soy, E., Priller, J., Spruth, E., Altenstein, S., Buerger, K., Catak, C., Janowitz, D.,
Perneczky, R., Utecht, J., Laske, C., Buchmann, M., Schneider, A., Fliessbach, K.,
Kalbhen, P., Heneka, M.T., Brosseron, F., Spottke, A., Roy, N., Teipel, S.J., Kili-
mann, I., Wiltfang, J., Bartels, C., Düzel, E., Dobisch, L., Metzger, C., Meiberth, D.,
Ramirez, A., Jessen, F., Wagner, M., 2019. Which features of subjective cognitive
decline are related to amyloid pathology? Findings from the DELCODE study.
Alzheimers. Res. Ther. 11, 1–14. doi: 10.1186/s13195-019-0515-y . 
Mielke, M.M., Syrjanen, J.A., Blennow, K., Zetterberg, H., Skoog, I., Vemuri, P.,
Machulda, M.M., Graff-Radford, J., Knopman, D.S., Jack, C.R., Petersen, R.C.,
Kern, S., 2019. Comparison of variables associated with cerebrospinal fluid
neurofilament, total-tau, and neurogranin. Alzheimers Dement. 15, 1437–1447.
doi: 10.1016/j.jalz.2019.07.009 . 
Milà-Alomà, M., Salvadó, G., Gispert, J.D., Vilor-Tejedor, N., Grau-Rivera, O., Sala-
Vila, A., Sánchez-Benavides, G., Arenaza-Urquijo, E.M., Crous-Bou, M., González-
de-Echávarri, J.M., Minguillón, C., Fauria, K., Simon, M., Kollmorgen, G., Zetter-
burg, H., Blennow, K., Suárez-Calvet, M., Molinuevo, J.L., 2020. Amyloid-
β , tau, synaptic, neurodegeneration and glial biomarkers in the preclin-
ical stage of the Alzheimer’s continuum. Alzheimers Dement. 1–14. doi:
10.1002/ALZ.12131 . 
Molinuevo, J.L., Gramunt, N., Gispert, J.D., Fauria, K., Esteller, M., Minguillon, C.,
Sánchez-Benavides, G., Huesa, G., Morán, S., Dal-Ré, R., Camí, J., 2016. The ALFA
project: A research platform to identify early pathophysiological features of
Alzheimer’s disease.. Alzheimers Dement. 2, 82–92. doi: 10.1016/j.trci.2016.02.
003 . 
Pereira, J.B., Westman, E., Hansson, O., Neuroimaging, D., 2017. Association between
cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atro-
phy in Alzheimer’s disease. Neurobiol. Aging. doi: 10.1016/j.neurobiolaging.2017.
06.002 . 
Perrotin, A., de Flores, R., Lamberton, F., Poisnel, G., La Joie, R., de la Sayette, V.,
Mézenge, F., Tomadesso, C., Landeau, B., Desgranges, B., Chételat, G., 2015. Hip-
pocampal subfield volumetry and 3D surface mapping in subjective cognitive
decline. J. Alzheimers. Dis. 48 (suppl 1), S141–S150. doi: 10.3233/JAD-150087 . 
Rami, L., Mollica, M.A., Garcfa-Sanchez, C., Saldafia, J., Sanchez, B., Sala, I., Valls-
Pedret, C., Castellvi, M., Olives, J., Molinuevo, J.L., 2014. The subjective cognitive
decline questionnaire (SCD-Q): a validation study. J. Alzheimers Dis. 41, 453–
466. doi: 10.3233/JAD-132027 . 
Rodríguez-Gómez, O., Abdelnour, C., Jessen, F., Valero, S., Boada, M., 2015. Influence
of sampling and recruitment methods in studies of subjective cognitive decline.
J. Alzheimers Dis. 48, S99–S107. doi: 10.3233/JAD-150189 . 
Scheef, L., Spottke, A., Daerr, M., Joe, A., Striepens, N., Kölsch, H., Popp, J., Daa-
men, M., Psych, D., Gorris, D., Heneka, M.T., Boecker, H., Biersack, H.J., Maier, W.,
Schild, H.H., Wagner, M., Jessen, F., 2012. Glucose metabolism, gray matter struc-
ture, and memory decline in subjective memory impairment. Neurology 79,
1332–1339. doi: 10.1212/WNL.0b013e31826c1a8d . Snitz, B.E., Lopez, O.L., McDade, E., Becker, J.T., Cohen, A.D., Price, J.C., Mathis, C.A.,
Klunk, W.E., 2015. Amyloid- β imaging in older adults presenting to a mem-
ory clinic with subjective cognitive decline: a pilot study. J. Alzheimers. Dis. 48
(suppl 1), S151–S159. doi: 10.3233/JAD-150113 . 
Valech, N., Tort-Merino, A., Coll-Padrós, N., Olives, J., León, M., Rami, L., Molin-
uevo, J.L., 2018. Executive and language subjective cognitive decline complaints
discriminate preclinical Alzheimer’s disease from normal aging. J. Alzheimers.
Dis. 61, 689–703. doi: 10.3233/JAD-170627 . 
Van Der Gucht, A., Verger, A., Yagdigul, Y., Poussier, S., Joly, L., Watfa, G., Benetos, A.,
Karcher, G., Marie, P.-Y., 2015. Complementarity of visual and voxel-based FDG-
PET analysis to detect MCI-like hypometabolic pattern in elderly patients with
hypertension and isolated memory complaints. Acta Radiol. 56, 980–989. doi: 10.
1177/0284185114542366 . 
Weston, P.S.J., Poole, T., Ryan, N.S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R.,
Malone, I.B., Ahsan, R.L., Pemberton, H., Klimova, J., Mead, S., Blennow, K.,
Rossor, M.N., Schott, J.M., Zetterberg, H., Fox, N.C., 2017. Serum neurofilament
light in familial Alzheimer disease. Neurology 89, 2167–2175. doi: 10.1212/wnl.
0 0 0 0 0 0 0 0 0 0 0 04667 . 
Wolfsgruber, S., Kleineidam, L., Guski, J., Polcher, A., Frommann, I., Roeske, S.,
Spruth, E.J., Franke, C., Priller, J., Kilimann, I., Teipel, S., Buerger, K., Janowitz, D.,
Laske, C., Buchmann, M., Peters, O., Menne, F., Casan, M.F., Wiltfang, J., Bar-
tels, C., Düzel, E., Metzger, C., Glanz, W., Thelen, M., Spottke, A., Ramirez, A.,
Kofler, B., Fließbach, K., Schneider, A., Heneka, M., Brosseron, F., Meiberth, D.,
Jessen, F., Wagner, M., 2020. Minor neuropsychological deficits in patients with
subjective cognitive decline. Neurology doi: 10.1212/WNL.0 0 0 0 0 0 0 0 0 0 010142 . 
Wolfsgruber, S., Molinuevo, J.L., Wagner, M., Teunissen, C.E., Rami, L., Coll-padrós,
N., Bouwman, F.H., Slot, R.E.R., Wesselman, L.M.P., Peters, O., Luther, K., Buerger,
K., Priller, J., Laske, C., Teipel, S., Spottke, A., Heneka, M.T., 2019. Prevalence of
abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive
decline : cross-sectional comparison of three European memory clinic samples.
Alzheimers Res. Ther. 11, 8. 1–11. https://doi.org/10.1186/s13195-018-0463-y . 
Wolfsgruber, S., Polcher, A ., Koppara, A ., Kleineidam, L., Frölich, L., Peters, O.,
Hüll, M., Rüther, E., Wiltfang, J., Maier, W., Kornhuber, J., Lewczuk, P., Jessen, F.,
Wagner, M., 2017. Cerebrospinal fluid biomarkers and clinical progression in
patients with subjective cognitive decline and mild cognitive impairment. J.
Alzheimers Dis. 58, 939–950. doi: 10.3233/JAD-161252 . 
Zetterberg, H., Skillbäck, T., Mattsson, N., Trojanowski, J.Q., Portelius, E., Shaw, L.M.,
Weiner, M.W., Blennow, K., 2016. Association of cerebrospinal fluid neurofila-
ment light concentration with Alzheimer disease progression. JAMA Neurol. 73,
60–67. doi: 10.1001/jamaneurol.2015.3037 . 
Zigmond, A. , Snalth, R. , 1983. The hospital anxiety and depression scale. Acta Psy-
chiatr. Scand. 67, 361–370 . 
